Trials / Recruiting
RecruitingNCT07239596
Phase Ib/II Clinical Study of SHR-8068 Combined With Adebrelimab and Other Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom
An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination With Adebrelimab and Other Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 139 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated the safety and efficacy of SHR-8068 in combination with Adebrelimab and other anti-tumor drugs in the treatment of advanced renal cell carcinoma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-8068；Adebrelimab ；Bevacizumab | SHR-8068+ Adebrelimab + Bevacizumab |
| DRUG | SHR-8068；Adebrelimab ；HS-10516 | SHR-8068+ Adebrelimab +HS-10516 |
| DRUG | SHR-8068； Adebrelimab ； Bevacizumab ；HRS-10516 | SHR-8068+ Adebrelimab + Bevacizumab +HRS-10516 |
Timeline
- Start date
- 2026-01-06
- Primary completion
- 2030-12-01
- Completion
- 2030-12-01
- First posted
- 2025-11-20
- Last updated
- 2026-03-16
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07239596. Inclusion in this directory is not an endorsement.